Leflunomide Zentiva (Leflunomide)

Leflunomide works by inhibiting dihydroorotate dehydrogenase, an enzyme essential for de novo pyrimidine synthesis. This blockade limits the proliferation of activated T‑lymphocytes, thereby dampening the autoimmune activity that contributes to joint inflammation and tissue damage in rheumatoid and psoriatic arthritis.

The appropriate dose of Leflunomide Zentiva is determined by the prescribing healthcare professional based on the individual’s disease severity, prior treatment response, liver function, and overall health status. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Leflunomide is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of a high risk of fetal harm. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may affect the infant.

To order Leflunomide Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required import documentation) and delivery timelines.

Compared with methotrexate, another first‑line DMARD, leflunomide offers a similar efficacy in controlling disease activity but has a different safety profile, with less hepatic toxicity but a higher risk of hypertension and rare severe skin reactions. Biologic agents provide greater potency for refractory disease but are administered by injection and are generally more costly.

Leflunomide Zentiva should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and store them out of reach of children to maintain product stability and potency.

Leflunomide Zentiva is taken orally, usually as a tablet swallowed whole with water. The exact dosing schedule, including any loading dose, is set by the prescriber based on the patient’s clinical condition and laboratory monitoring requirements.

The most serious risks include severe liver injury or hepatitis, aplastic anemia leading to low blood cell counts, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver function, complete blood counts, and any signs of severe skin or respiratory symptoms.

Leflunomide Zentiva should not be used by pregnant women, individuals with pre‑existing severe liver disease, patients with uncontrolled hypertension, or those with known hypersensitivity to leflunomide or its metabolites. Caution is also advised for patients with significant renal impairment or active infections.